Pharmacodynamics and pharmacokinetics of DX-9065a in renal impairment.

被引：0
|
作者：
Depasse, F
Kunitada, S
Busson, J
Haque, N
Samama, MM
机构：
[1] LCL, Ivry, France
[2] Daiichi Pharmaceut Co Ltd, London, England
[3] Hop Hotel Dieu, Serv Hematol Biol, Paris, France
[4] Daiichi Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页码：121B / 121B
页数：1
相关论文
共 50 条
  • [41] SELECTIVE FACTOR XA INHIBITOR, DX-9065A, SUPPRESSED HYPERCOAGULABLE STATE DURING HEMODIALYSIS IN CYNOMORGUS MONKEYS
    HARA, T
    MORISHIMA, Y
    KUNITADA, S
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1311 - 1311
  • [42] The pharmacokinetics of the anti-convulsant drug remacemide hydrochloride in renal impairment.
    Blakey, GE
    Lockton, JA
    Hall, DE
    Mant, T
    EPILEPSIA, 1999, 40 : 251 - 251
  • [43] Pharmacodynamics of alcohol: Substantial differences in skills impairment.
    Ellinwood, EH
    Gupta, SK
    Muir, KT
    Powell, JR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : OIIB4 - OIIB4
  • [44] DX-9065a, a specific factor Xa inhibitor, inhibits the upregulation of tissue factor in the rat DIC model
    Akahane, K
    Okamoto, K
    Todoroki, H
    Higure, A
    Kitahara, K
    Kikuchi, M
    Itoh, H
    Ohsato, K
    THROMBOSIS AND HAEMOSTASIS, 1999, : 582 - 582
  • [45] Possible mechanisms of less bleeding tendency of DX-9065a. Antithrombotic effective dose of DX-9065a did not affect the blood viscosity at low shear stress and the platelet retention to glass beads
    Tanabe, K
    Honda, Y
    Morishima, Y
    Kunitada, S
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2022 - P2022
  • [46] IN-VIVO EVALUATION OF DX-9065A, A SYNTHETIC FACTOR-XA INHIBITOR, IN EXPERIMENTAL VEIN GRAFT MODEL
    KIM, DI
    KAMBAYASHI, J
    SHIBUYA, T
    KAWASAKI, T
    SHIBA, E
    SAKON, M
    MORI, T
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 672 - 672
  • [47] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban - II. Effects on fibrinolysis
    Nagashima, H
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (52) : 50445 - 50449
  • [48] Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment
    Dingemanse, J
    Halabi, A
    Kleinbloesem, CH
    Heinig, R
    Blume, H
    THERAPEUTIC DRUG MONITORING, 1999, 21 (03) : 310 - 316
  • [49] BEMIPARIN PHARMACODYNAMICS/PHARMACOKINETICS IN YOUNG, ELDERLY AND SUBJECTS WITH RENAL IMPAIRMENT
    Martinez-Gonzalez, J.
    Rico, S.
    Ballester, M. R.
    Gutierro, I.
    Borrell, M.
    Ayani, I.
    Antonijoan, R. -M.
    Gich, I.
    Fontcuberta, J.
    THROMBOSIS RESEARCH, 2014, 133 : S33 - S33
  • [50] Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment
    Butler, Kathleen
    Teng, Renli
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (09): : 1388 - 1398
12345